Skip to main content

Table 4 Sequential measurements of clinical efficacy outcomes

From: Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial

Variables

Baseline

Week 1

Week 2

Week 6

Week 12

Week 24

Estimated marginal means (SE)

HDRS

 Mirtazapine

23.0 (1.2)

19.0 (1.3)

15.5 (1.3)

9.6 (1.4)

9.3 (1.5)

5.9 (1.6)

 SSRIs

23.1 (0.9)

19.2 (0.9)

16.9 (0.9)

12.9 (1.0)

9.5 (1.0)

5.4 (1.1)

  Sertraline

23.2 (1.1)

19.1 (1.2)

16.3 (1.1)

12.1 (1.2)

8.7 (1.3)

5.3 (1.4)

  Paroxetine

22.9 (1.5)

19.4 (1.5)

17.8 (1.5)

14.6 (1.7)

11.2 (1.8)

5.8 (2.0)

SDS

 Mirtazapine

56.0 (1.7)

52.4 (1.8)

46.6 (1.8)

44.0 (1.9)

43.7 (2.1)

38.0 (2.2)

 SSRIs

57.6 (1.3)

54.8 (1.3)

52.8 (1.3)

48.7 (1.4)

44.9 (1.5)

41.8 (1.6)

  Sertraline

57.4 (1.6)

54.1 (1.7)

51.2 (1.6)

47.2 (1.7)

42.4 (1.8)

40.3 (1.9)

  Paroxetine

57.9 (2.1)

56.1 (2.1)

55.0 (2.1)

51.4 (2.3)

49.8 (2.5)

44.5 (2.8)

AIS

 Mirtazapine

11.5 (0.9)

8.4 (0.9)

6.6 (0.9)

5.8 (1.0)

6.8 (1.1)

5.0 (1.1)

 SSRIs

12.9 (0.6)

10.2 (0.6)

9.3 (0.6)

7.5 (0.7)

6.6 (0.7)

5.5 (0.8)

  Sertraline

12.8 (0.8)

10.0 (0.8)

8.1 (0.8)

6.9 (0.8)

5.3 (0.9)

4.6 (1.0)

  Paroxetine

13.1 (1.0)

10.5 (1.0)

11.3 (1.0)

8.8 (1.2)

9.2 (1.2)

7.2 (1.4)

CGI-S

 Mirtazapine

4.4 (0.2)

3.8 (0.2)

3.2 (0.2)

2.8 (0.2)

2.6 (0.2)

1.8 (0.2)

 SSRIs

4.3 (0.1)

4.0 (0.1)

3.6 (0.1)

3.1 (0.1)

2.7 (0.1)

2.1 (0.2)

  Sertraline

4.4 (0.2)

4.0 (0.2)

3.6 (0.2)

3.0 (0.2)

2.6 (0.2)

2.1 (0.2)

  Paroxetine

4.2 (0.2)

4.1 (0.2)

3.6 (0.2)

3.5 (0.2)

3.0 (0.3)

2.0 (0.3)

  1. All values are based on estimated marginal means using a linear mixed effects model for repeated measures data
  2. SSRI selective serotonin reuptake inhibitor, HDRS 17-item Hamilton depression rating scale, SDS Zung self-rating depression scale, AIS Athens insomnia scale, SE standard error